TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26078574

Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg once daily for 8 weeks
Number of subjects: 305

Group type: COMPARATOR
Intervention: Esomeprazole 20 mg once daily for 2 weeks
Number of subjects: 305
Study: 23522788

Group type: EXPERIMENTAL
Intervention: HIV/HAART patients
Number of subjects: 250
Study: 21528594

Group type: EXPERIMENTAL
Intervention: Acupuncture on single-point (Shiqizhui EX-B 8)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Acupuncture on multi-point (Shiqizhui EX-B 8, Diji SP 8, Ciliao BL 32, Sanyinjiao SP 6)
Number of subjects: 63
Study: 19401665

Group type: EXPERIMENTAL
Intervention: Sevoflurane with remifentanil (group SR)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sevoflurane alone (group S)
Number of subjects: 50
Study: 16723327

Group type: EXPERIMENTAL
Intervention: Feeling-of-Knowing task in patients with schizophrenia
Number of subjects: 32

Group type: COMPARATOR
Intervention: Feeling-of-Knowing task in control subjects
Number of subjects: 32
Study: 15109760

Group type: COMPARATOR
Intervention: Pes planus group
Number of subjects: 0
Study: 11157326

Group type: EXPERIMENTAL
Intervention: 25 microg vitamin D3/d
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: 100 microg vitamin D3/d
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (not taking vitamin D3)
Number of subjects: 61
Study: 9622114

Group type: EXPERIMENTAL
Intervention: Upper Limit of Vulnerability (ULV) measurement
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Amiodarone therapy
Number of subjects: 13

Group type: COMPARATOR
Intervention: CPK-MB assessment
Number of subjects: 13
Study: 7938648

Group type: EXPERIMENTAL
Intervention: Dexamethasone (Dexaven)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No dexamethasone (Control)
Number of subjects: 0
Study: 3077320

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group therapy (stress inoculation training)
Number of subjects: 69
Study: 31982882

Group type: EXPERIMENTAL
Intervention: Online haemodiafiltration (OL-HDF)
Number of subjects: 15

Group type: COMPARATOR
Intervention: High-flux haemodialysis (HF-HD)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Sensitivity analysis excluding outliers
Number of subjects: 15
Study: 30502505

Group type: EXPERIMENTAL
Intervention: Lusutrombopag (3 mg once daily for up to 7 days)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 27858108

Group type: EXPERIMENTAL
Intervention: Fostamatinib with food
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fostamatinib with ranitidine (antacid)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fostamatinib (general)
Number of subjects: 0
Study: 26453483

Group type: EXPERIMENTAL
Intervention: 6-tip diet (6-TD)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Low-protein diet (LPD) 0.8 g/kg/day
Number of subjects: 57
Study: 25095773

Group type: EXPERIMENTAL
Intervention: Ethanol consumption (40% ethanol drinks)
Number of subjects: 8
Study: 21853348

Group type: EXPERIMENTAL
Intervention: Qingre Huoxue Decoction (QRHXD)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Qingre Huoxue Decoction plus methotrexate (QRHXD+MTX)
Number of subjects: 86
Study: 19562716

Group type: EXPERIMENTAL
Intervention: Oral branched-chain amino acids (BCAAs) 12.45 g/day for at least 1 year
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control (no BCAAs)
Number of subjects: 56
Study: 17223384

Group type: EXPERIMENTAL
Intervention: Low-frequency rTMS (0.5Hz for 5 consecutive days at 100% of rMT)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Low-frequency rTMS (3000 pulses)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Low-frequency rTMS
Number of subjects: 35
Study: 15339742

Group type: EXPERIMENTAL
Intervention: Localized proton magnetic resonance spectroscopy (MRS)
Number of subjects: 2349
Study: 12096294

Group type: EXPERIMENTAL
Intervention: Computer-based nursing intervention (9 visits over 18 weeks)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 109
Study: 9500302

Group type: EXPERIMENTAL
Intervention: Remission from cocaine and alcohol dependence during IOP
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Higher AIDS risk behavior scores in the prior 6 months
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Individualized relapse prevention aftercare
Number of subjects: 138

Group type: COMPARATOR
Intervention: Standard 12‐step focused group aftercare
Number of subjects: 138
Study: 7624463

Group type: EXPERIMENTAL
Intervention: High somatic attribution scores (S-FAS)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Low somatic attribution scores (S-FAS)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Both groups at follow-up visit
Number of subjects: 170
Study: 2676391

Group type: EXPERIMENTAL
Intervention: Conventional therapy including positive end-expiratory pressure (PEEP)
Number of subjects: 0
Study: 362830

Group type: EXPERIMENTAL
Intervention: cis(Z)-clopenthixol
Number of subjects: 57

Group type: COMPARATOR
Intervention: clopenthixol
Number of subjects: 57
Study: 31395587

Group type: EXPERIMENTAL
Intervention: Presentation framed towards pulmonary embolus (PE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Presentation framed away from pulmonary embolus (PE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Presentation framed towards interstitial lung disease (ILD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control presentation (identical for all)
Number of subjects: 0
Study: 27838640

Group type: EXPERIMENTAL
Intervention: Preoperative itraconazole (4 weeks)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Postoperative itraconazole (4 weeks)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no itraconazole)
Number of subjects: 100
Study: 26048096

Group type: EXPERIMENTAL
Intervention: Dacomitinib 30 mg
Number of subjects: 25
Study: 23819229

Group type: EXPERIMENTAL
Intervention: Floating acupuncture at Tianying point
Number of subjects: 90

Group type: COMPARATOR
Intervention: Warm needling therapy at Tianying point
Number of subjects: 90
Study: 21985413

Group type: EXPERIMENTAL
Intervention: 135 mg minocycline tablet formulation
Number of subjects: 14
Study: 19282143

Group type: EXPERIMENTAL
Intervention: Combination therapy (sulfasalazine, methotrexate, prednisolone)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Monotherapy (sulfasalazine)
Number of subjects: 0
Study: 16648512

Group type: EXPERIMENTAL
Intervention: TPZ/CIS (tirapazamine and cisplatin)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Chemoboost (cisplatin and infusional fluorouracil)
Number of subjects: 45
Study: 15001600

Group type: EXPERIMENTAL
Intervention: Oral glutamine (0.7 g/kg.d)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH) (0.3 mg/kg.wk)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Combined GLN and rhGH regimen
Number of subjects: 9

Group type: COMPARATOR
Intervention: Baseline (no treatment)
Number of subjects: 9
Study: 11893948

Group type: EXPERIMENTAL
Intervention: Vaginal cones
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pressure biofeedback
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pelvic floor exercises alone
Number of subjects: 0
Study: 9304202

Group type: EXPERIMENTAL
Intervention: Hymecromone 400 mg i.v.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 8254832

Group type: EXPERIMENTAL
Intervention: Citrate therapy (6 to 8 gm. per day)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control (hygienic measures only)
Number of subjects: 70
Study: 3533270

Group type: EXPERIMENTAL
Intervention: Nimodipine
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 31521870

Group type: EXPERIMENTAL
Intervention: Tyrosine (2.0 g)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo (cellulose)
Number of subjects: 70
Study: 29466352

Group type: EXPERIMENTAL
Intervention: Power Over Pain‐Coaching (POP‐C) intervention
Number of subjects: 310
Study: 26971267

Group type: EXPERIMENTAL
Intervention: Measured FVA group (preoperative measurement of FVA)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (fixed FVA at 7°)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 120
Study: 24884753

Group type: EXPERIMENTAL
Intervention: Behavioral support intervention (office practice and peer coach)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Informational brochures about CHD risk factors (control)
Number of subjects: 280
Study: 22517103

Group type: EXPERIMENTAL
Intervention: Perampanel 2 mg/day
Number of subjects: 706

Group type: EXPERIMENTAL
Intervention: Perampanel 4 mg/day
Number of subjects: 706

Group type: EXPERIMENTAL
Intervention: Perampanel 8 mg/day
Number of subjects: 706

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 706
Study: 15221324

Group type: EXPERIMENTAL
Intervention: Therapeutic amniocentesis
Number of subjects: 17

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 17
Study: 12042546

Group type: EXPERIMENTAL
Intervention: Surfaxin lavage (8 mL/kg dilute Surfaxin 2.5 mg/mL, instilled into each lung, repeated twice, final lavage with 10 mg/mL)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 22
Study: 10534600

Group type: EXPERIMENTAL
Intervention: Oral ketamine (20 mg increased daily to a maximum of 100 mg)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Oral ketamine
Number of subjects: 21
Study: 8519711

Group type: EXPERIMENTAL
Intervention: 5% lidocaine in 7.5% dextrose (drug A)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 5% lidocaine in 2.7% dextrose (drug C)
Number of subjects: 44

Group type: COMPARATOR
Intervention: 0.5% bupivacaine in 8.25% dextrose (drug B)
Number of subjects: 44
Study: 2110937

Group type: EXPERIMENTAL
Intervention: Guar gum (5 g t.i.d. with meals)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 373940

Group type: EXPERIMENTAL
Intervention: Oral isosorbide dinitrate (ISDN)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 29098875

Group type: EXPERIMENTAL
Intervention: Immunosuppression (intravenous cyclophosphamide up to 1 g/day for two days and methylprednisolone 1 g/day for three days, and then oral dexamethasone 8 mg three-times-a-day for 14 days)
Number of subjects: 299

Group type: COMPARATOR
Intervention: Saline and placebo tablets (control group)
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Immunosuppression
Number of subjects: 299
Study: 28823409

Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 1997

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 1997
Study: 25062806

Group type: EXPERIMENTAL
Intervention: Brief intervention delivered by an Occupational Health nurse
Number of subjects: 57

Group type: COMPARATOR
Intervention: No delivery of brief intervention (control group)
Number of subjects: 57
Study: 23609341

Group type: EXPERIMENTAL
Intervention: Sequential (exercise first)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Simultaneous intervention
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Diet-first intervention
Number of subjects: 200

Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Exercise-first intervention
Number of subjects: 200
Study: 21373181

Group type: EXPERIMENTAL
Intervention: Looming sounds
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Receding sounds
Number of subjects: 2

Group type: COMPARATOR
Intervention: Orthographic plws without sound
Number of subjects: 2
Study: 18202556

Group type: EXPERIMENTAL
Intervention: Normal saline
Number of subjects: 102

Group type: COMPARATOR
Intervention: Heparinized saline
Number of subjects: 102
Study: 16793995

Group type: EXPERIMENTAL
Intervention: Randomized controlled trials (RCTs)
Number of subjects: 164
Study: 14676740

Group type: EXPERIMENTAL
Intervention: 0.625 mg/day conjugated equine estrogen only
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Estrogen plus 2.5 mg/day medroxyprogesterone acetate
Number of subjects: 246

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Adherent women (those who took > or = 80% of pills)
Number of subjects: 246
Study: 10731503

Group type: EXPERIMENTAL
Intervention: Iron and folic acid supplements with zinc (15 mg Zn)
Number of subjects: 645

Group type: COMPARATOR
Intervention: Iron and folic acid supplements without zinc
Number of subjects: 645

Group type: EXPERIMENTAL
Intervention: Iron and folic acid supplements (both with and without zinc)
Number of subjects: 645
Study: 9052292

Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 58

Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 58
Study: 1392218

Group type: EXPERIMENTAL
Intervention: Instruction in personal control over noise
Number of subjects: 105

Group type: COMPARATOR
Intervention: No instruction in personal control over noise
Number of subjects: 105

Group type: COMPARATOR
Intervention: Quiet condition
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: CCU sound levels
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Sensitivity to noise
Number of subjects: 105
Study: 3890398

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine (20 micrograms dose), repeated one and six months after initial administration
Number of subjects: 146

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine (20 micrograms dose)
Number of subjects: 146
Study: 31932389

Group type: EXPERIMENTAL
Intervention: Topical Dynamiclear
Number of subjects: 292

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 292
Study: 28873333

Group type: EXPERIMENTAL
Intervention: Echocardiography-guided therapy
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 90
Study: 26988662

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) program
Number of subjects: 1635

Group type: COMPARATOR
Intervention: Health Education (HE) program
Number of subjects: 1635
Study: 24816691

Group type: EXPERIMENTAL
Intervention: Palatal implant surgery
Number of subjects: 30

Group type: COMPARATOR
Intervention: Radiofrequency surgery
Number of subjects: 30
Study: 22616580

Group type: EXPERIMENTAL
Intervention: Sorafenib plus capecitabine
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Sorafenib plus gemcitabine or capecitabine
Number of subjects: 4

Group type: COMPARATOR
Intervention: Sorafenib plus paclitaxel
Number of subjects: 4

Group type: COMPARATOR
Intervention: Sorafenib plus docetaxel and/or letrozole
Number of subjects: 4
Study: 20192864

Group type: COMPARATOR
Intervention: Control Group (CG) - 15 patients without periapical lesions
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Test Group (TG) - 15 patients with periapical lesions
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups (CG and TG)
Number of subjects: 30
Study: 17942510

Group type: EXPERIMENTAL
Intervention: Robot-assisted gait training (RAGT)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Conventional walking training (CWT)
Number of subjects: 35
Study: 16207152

Group type: EXPERIMENTAL
Intervention: rostafuroxin 0.05 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: rostafuroxin 0.15 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: rostafuroxin 0.5 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: rostafuroxin 1.5 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: rostafuroxin 5.0 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: rostafuroxin (all doses)
Number of subjects: 0
Study: 11910343

Group type: EXPERIMENTAL
Intervention: Propranolol (139 +/- 9 mg/d during 39 +/- 2 days)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Octreotide (100 microg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Octreotide (200 microg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 10937986

Group type: EXPERIMENTAL
Intervention: Aspirin or Warfarin
Number of subjects: 279

Group type: COMPARATOR
Intervention: No anti-thrombotic therapy
Number of subjects: 279
Study: 8726544

Group type: EXPERIMENTAL
Intervention: Naloxone (0.6 mg in three divided doses)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 8
Study: 1820641

Group type: EXPERIMENTAL
Intervention: Daily artesunate regimen (200 mg initial dose followed by 100 mg daily for 4 days)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Twice daily artesunate regimen (100 mg 12 hourly for 2 doses on the first day, followed by 50 mg 12 hourly for another 8 doses)
Number of subjects: 59
Study: 7042356

Group type: EXPERIMENTAL
Intervention: Indoprofen (800 mg/day)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Indomethacin (100 mg/day)
Number of subjects: 41
Study: 30572071

Group type: EXPERIMENTAL
Intervention: Hypothermia (goal temperature 32–34 °C)
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Normothermia (goal temperature 36–37.5 °C)
Number of subjects: 281
Study: 27981462

Group type: EXPERIMENTAL
Intervention: Educational leaflet about psoriatic arthritis (PsA)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Study information alone (Control)
Number of subjects: 191
Study: 26071920

Group type: EXPERIMENTAL
Intervention: Treatment for mild GDM
Number of subjects: 958
Study: 23433504

Group type: EXPERIMENTAL
Intervention: Oxytocin (24 IU intranasal)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 21969851

Group type: EXPERIMENTAL
Intervention: UC781 gel 0.25%
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: UC781 gel 0.1%
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 36
Study: 19725440

Group type: EXPERIMENTAL
Intervention: Potential-guided approach
Number of subjects: 228

Group type: COMPARATOR
Intervention: Anatomic-guided approach
Number of subjects: 228
Study: 17597643

Group type: EXPERIMENTAL
Intervention: Fermented milk containing Lactobacillus casei (100 mL, 10^8 cfu/mL)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 187
Study: 15173473

Group type: EXPERIMENTAL
Intervention: Screened group (N = 42)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control group (N = 47)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control group with vitamin E deficiency (alpha-T < 300 microg/dl)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Overall study population
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Patients with low plasma alpha-tocopherol levels at diagnosis
Number of subjects: 89
Study: 11432470

Group type: COMPARATOR
Intervention: Standard uncoated ECC with systemic heparin 400 IE/kg
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Heparin-coated ECC with systemic heparin 400 IE/kg
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Heparin-coated ECC with reduced systemic heparin 150 IE/kg
Number of subjects: 243
Study: 9821850

Group type: EXPERIMENTAL
Intervention: Benazepril 10 mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Nitrendipine 20 mg
Number of subjects: 50
Study: 7523271

Group type: EXPERIMENTAL
Intervention: Interferon-alpha
Number of subjects: 8
Study: 2557274

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (2 puffs of 2 mg each twice daily)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo (2 puffs twice daily)
Number of subjects: 131
Study: 31280694

Group type: EXPERIMENTAL
Intervention: Culture-sensitive pain neuroscience education (PNE)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Standard pain neuroscience education (PNE)
Number of subjects: 29
Study: 31096828

Group type: EXPERIMENTAL
Intervention: Skin graft technique
Number of subjects: 14

Group type: COMPARATOR
Intervention: Graftless technique
Number of subjects: 14
Study: 29423885

Group type: EXPERIMENTAL
Intervention: Radiofrequency (RF) ablation of the basivertebral nerve (BVN)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 225
Study: 27278517

Group type: EXPERIMENTAL
Intervention: Moderate catheter stability VisiTag setting (3-mm distance limit for at least 5 s, minimum contact force of 8 g over 25% of the set time period, target FTI ≥300 g*s)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Strict catheter stability VisiTag setting (3-mm distance limit for at least 10 s, minimum contact force of 10 g over 50% of the set time period, target FTI ≥400 g*s)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Both groups (Moderate and Strict catheter stability settings)
Number of subjects: 54
Study: 24781054

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with SSRIs (Selective Serotonin Reuptake Inhibitors)
Number of subjects: 76

Group type: COMPARATOR
Intervention: SSRIs only (Control Group)
Number of subjects: 76
Study: 22092915

Group type: EXPERIMENTAL
Intervention: Bifidobacterium breve M‐16V combined with a prebiotic oligosaccharide mixture (synbiotic)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (infant formula without synbiotics)
Number of subjects: 90
Study: 20231786

Group type: EXPERIMENTAL
Intervention: Interferon beta 1B (IFNB 1b)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (not taking IFNB 1b)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both groups (IFNB 1b and control)
Number of subjects: 32
Study: 18605602

Group type: EXPERIMENTAL
Intervention: Guided Tissue Regeneration (GTR) with anorganic bovine bone and resorbable collagen membrane
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (no grafts or membranes)
Number of subjects: 34
Study: 15855243

Group type: EXPERIMENTAL
Intervention: Sucrose 24%
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo (sterile water)
Number of subjects: 23
Study: 11478144

Group type: EXPERIMENTAL
Intervention: Ondansetron hydrochloride (OND group)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Concurrent use of ondansetron and dexamethasone (DEX group)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Dexamethasone (part of DEX group)
Number of subjects: 78
Study: 9203804

Group type: EXPERIMENTAL
Intervention: O2 night (LTOT)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Air night (room air)
Number of subjects: 16
Study: 8424733

Group type: EXPERIMENTAL
Intervention: 0.6 mg scopolamine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 2.5 mg methscopolamine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60